Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

Published:2023-05-26 Issue:21 Volume:72 Page:579-588
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Link-Gelles Ruth,Weber Zachary A.,Reese Sarah E.,Payne Amanda B.,Gaglani Manjusha,Adams Katherine,Kharbanda Anupam B.,Natarajan Karthik,DeSilva Malini B.,Dascomb Kristin,Irving Stephanie A.,Klein Nicola P.,Grannis Shaun J.,Ong Toan C.,Embi Peter J.,Dunne Margaret M.,Dickerson Monica,McEvoy Charlene,Arndorfer Julie,Naleway Allison L.,Goddard Kristin,Dixon Brian E.,Griggs Eric P.,Hansen John,Valvi Nimish,Najdowski Morgan,Timbol Julius,Rogerson Colin,Fireman Bruce,Fadel William F.,Patel Palak,Ray Caitlin S.,Wiegand Ryan,Ball Sarah,Tenforde Mark W.

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference4 articles.

1. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults—VISION Network, nine states, September–November 2022.;Tenforde;MMWR Morb Mortal Wkly Rep,2023

2. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 states, August 2021–January 2022.;Thompson;MMWR Morb Mortal Wkly Rep,2022

3. Effectiveness of monovalent mRNA COVID-19 vaccination in preventing COVID-19–associated invasive mechanical ventilation and death among immunocompetent adults during the Omicron variant period—IVY Network, 19 U.S. states, February 1, 2022–January 31, 2023.;DeCuir;MMWR Morb Mortal Wkly Rep,2023

4. Effectiveness of COVID-19 mRNA vaccines against COVID-19–associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance—VISION Network, 10 states, December 2021–August 2022.;Britton;MMWR Morb Mortal Wkly Rep,2022

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among residents of US nursing homes, November 2022 – March 2023;Vaccine;2024-10

2. A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine;Vaccine;2024-09

3. Quantifying the social value of a universal COVID-19 vaccine and incentivizing its development;Review of Economic Design;2024-08-30

4. Palliative care and COVID-19: acknowledging past mistakes to forge a better future;Frontiers in Medicine;2024-07-25

5. Quantifying Disparities in COVID-19 Vaccination Rates by Rural and Urban Areas: Cross-Sectional Observational Study;JMIR Public Health and Surveillance;2024-07-19